Fremanezumab meets goals as a prophylactic treatment for migraine

28 January 2020
migraine_headache_patient_big

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) has announced positive preliminary results from two, Phase II/III trials for fremanezumab as a prophylactic migraine drug.

Fremanezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody. It is administered as a subcutaneous injection for the prevention of chronic and episodic migraine. Fremanezumab is under development in Japan by Otsuka, which entered into an exclusive license agreement with Teva Pharmaceutical Industries (NYSE: TEVA) in May 2017 for development and sales in Japan.

In June last year, Teva gained European approval for the drug, which carries the trade name Ajovy. Ajovy received US Food and Drug Administration approval for the preventive treatment of migraine in adults in September 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology